Sign Up to like & get
recommendations!
0
Published in 2017 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02217-17
Abstract: ABSTRACT Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively. This once-daily, fixed-dose combination regimen demonstrated high sustained virologic response 12 weeks postdosing (SVR12) rates in CERTAIN-1 and…
read more here.
Keywords:
treatment;
infected patients;
certain certain;
certain studies ... See more keywords